| Year |
Citation |
Score |
| 2017 |
Patel NM, Michelini VV, Snell JM, Balu S, Hoyle AP, Parker JS, Hayward MC, Eberhard DA, Salazar AH, McNeillie P, Xu J, Huettner CS, Koyama T, Utro F, Rhrissorrakrai K, ... ... Bilal E, et al. Enhancing Next-Generation Sequencing-Guided Cancer Care Through Cognitive Computing. The Oncologist. PMID 29158372 DOI: 10.1634/Theoncologist.2017-0170 |
0.318 |
|
| 2015 |
Rhrissorrakrai K, Belcastro V, Bilal E, Norel R, Poussin C, Mathis C, Dulize RH, Ivanov NV, Alexopoulos L, Rice JJ, Peitsch MC, Stolovitzky G, Meyer P, Hoeng J. Understanding the limits of animal models as predictors of human biology: lessons learned from the sbv IMPROVER Species Translation Challenge. Bioinformatics (Oxford, England). 31: 471-83. PMID 25236459 DOI: 10.1093/Bioinformatics/Btu611 |
0.322 |
|
| 2015 |
Hormoz S, Bhanot G, Biehl M, Bilal E, Meyer P, Norel R, Rhrissorrakrai K, Dayarian A. Inter-species inference of gene set enrichment in lung epithelial cells from proteomic and large transcriptomic datasets. Bioinformatics (Oxford, England). 31: 492-500. PMID 25152231 DOI: 10.1093/Bioinformatics/Btu569 |
0.493 |
|
| 2015 |
Dayarian A, Romero R, Wang Z, Biehl M, Bilal E, Hormoz S, Meyer P, Norel R, Rhrissorrakrai K, Bhanot G, Luo F, Tarca AL. Predicting protein phosphorylation from gene expression: top methods from the IMPROVER Species Translation Challenge. Bioinformatics (Oxford, England). 31: 462-70. PMID 25061067 DOI: 10.1093/Bioinformatics/Btu490 |
0.535 |
|
| 2015 |
Biehl M, Sadowski P, Bhanot G, Bilal E, Dayarian A, Meyer P, Norel R, Rhrissorrakrai K, Zeller MD, Hormoz S. Inter-species prediction of protein phosphorylation in the sbv IMPROVER species translation challenge. Bioinformatics (Oxford, England). 31: 453-61. PMID 24994890 DOI: 10.1093/Bioinformatics/Btu407 |
0.492 |
|
| 2015 |
Labidi-Galy SI, Clauss A, Ng V, Duraisamy S, Elias KM, Piao HY, Bilal E, Davidowitz RA, Lu Y, Badalian-Very G, Györffy B, Kang UB, Ficarro S, Ganesan S, Mills GB, et al. Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene. 34: 373-83. PMID 24469047 DOI: 10.1038/Onc.2013.562 |
0.448 |
|
| 2015 |
Koyama T, Jones S, Utro F, Ma Y, Rhrissorrakrai K, Shen Y, Carmeli B, Jones M, Waks Z, Pleasance E, Norel R, Moore R, Bilal E, Mungall AJ, Beaty K, et al. Implementation of Watson Genomic Analytics processing to improve the efficiency of interpreting whole genome sequencing data on patients with advanced cancers. Journal of Clinical Oncology. 33: e12549-e12549. DOI: 10.1200/Jco.2015.33.15_Suppl.E12549 |
0.318 |
|
| 2013 |
Tarca AL, Lauria M, Unger M, Bilal E, Boue S, Kumar Dey K, Hoeng J, Koeppl H, Martin F, Meyer P, Nandy P, Norel R, Peitsch M, Rice JJ, Romero R, et al. Strengths and limitations of microarray-based phenotype prediction: lessons learned from the IMPROVER Diagnostic Signature Challenge. Bioinformatics (Oxford, England). 29: 2892-9. PMID 23966112 DOI: 10.1093/Bioinformatics/Btt492 |
0.329 |
|
| 2013 |
Mehta MS, Dolfi SC, Bronfenbrener R, Bilal E, Chen C, Moore D, Lin Y, Rahim H, Aisner S, Kersellius RD, Teh J, Chen S, Toppmeyer DL, Medina DJ, Ganesan S, et al. Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes. Plos One. 8: e69851. PMID 23922822 DOI: 10.1371/Journal.Pone.0069851 |
0.447 |
|
| 2013 |
Bilal E, Dutkowski J, Guinney J, Jang IS, Logsdon BA, Pandey G, Sauerwine BA, Shimoni Y, Moen Vollan HK, Mecham BH, Rueda OM, Tost J, Curtis C, Alvarez MJ, Kristensen VN, et al. Improving breast cancer survival analysis through competition-based multidimensional modeling. Plos Computational Biology. 9: e1003047. PMID 23671412 DOI: 10.1371/Journal.Pcbi.1003047 |
0.429 |
|
| 2013 |
Margolin AA, Bilal E, Huang E, Norman TC, Ottestad L, Mecham BH, Sauerwine B, Kellen MR, Mangravite LM, Furia MD, Vollan HK, Rueda OM, Guinney J, Deflaux NA, Hoff B, et al. Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Science Translational Medicine. 5: 181re1. PMID 23596205 DOI: 10.1126/Scitranslmed.3006112 |
0.447 |
|
| 2013 |
Poussin C, Alexopoulos L, Belcastro V, Bilal E, Mathis C, Meyer P, Norel R, Rice JJ, Stolovitzky G, Hoeng J, Peitsch M. Translational systems biology understanding the limits of animal models as predictors of human biology Embnet.Journal. 19: 30. DOI: 10.14806/Ej.19.A.624 |
0.302 |
|
| 2013 |
Labidi-Galy I, Clauss A, Ng V, Duraisamy S, Elias KM, Bilal E, Davidowitz RA, Lu Y, Badalian-Very G, Piao H, Kang U, Ficarro S, Ganesan S, Mills GB, Marto J, et al. Abstract B74: Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-B74 |
0.455 |
|
| 2012 |
Bilal E, Vassallo K, Toppmeyer D, Barnard N, Rye IH, Almendro V, Russnes H, Børresen-Dale AL, Levine AJ, Bhanot G, Ganesan S. Amplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancers. Plos One. 7: e38575. PMID 22719901 DOI: 10.1371/Journal.Pone.0038575 |
0.591 |
|
| 2012 |
Vermeer PD, Bell M, Lee K, Vermeer DW, Wieking BG, Bilal E, Bhanot G, Drapkin RI, Ganesan S, Klingelhutz AJ, Hendriks WJ, Lee JH. ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers. Plos One. 7: e30447. PMID 22279592 DOI: 10.1371/Journal.Pone.0030447 |
0.578 |
|
| 2012 |
Mehta MS, Dolfi S, Bronfenbrener R, Bilal E, Medina D, Haffty B, Toppmeyer D, Ganesan S, Hirshfield KM. Abstract 81: Role of GRM1 in breast cancer Cancer Research. 72: 81-81. DOI: 10.1158/1538-7445.Am2012-81 |
0.445 |
|
| 2011 |
Witkiewicz AK, Kline J, Queenan M, Brody JR, Tsirigos A, Bilal E, Pavlides S, Ertel A, Sotgia F, Lisanti MP. Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle (Georgetown, Tex.). 10: 1794-809. PMID 21521946 DOI: 10.4161/Cc.10.11.15675 |
0.427 |
|
| 2010 |
Bilal E, Alexe G, Yao M, Cong L, Kulkarni A, Ginjala V, Toppmeyer D, Ganesan S, Bhanot G. Identification of the YES1 Kinase as a Therapeutic Target in Basal-Like Breast Cancers. Genes & Cancer. 1: 1063-73. PMID 21779430 DOI: 10.1177/1947601910395583 |
0.601 |
|
| 2009 |
Tadigotla V, Alexe G, Sethi N, Bilal E, Huang C, Monti S, Tamayo P, DeLisi C, Bhanot G, Ganesan S. NF-κB Activation in Breast Cancer Occurs Via Different Mechanisms in Triple Negative and HER2+ Tumors with Lymphocytic Infiltrate. Cancer Research. 69: 1164-1164. DOI: 10.1158/0008-5472.Sabcs-09-1164 |
0.579 |
|
| 2009 |
Aly A, Yang Q, Bilal E, Yao M, Bhanot G, Toppmeyer D, Haffty B, Ganesan S. Abnormalities of 53BP1 in Basal-Like Breast Cancer. Cancer Research. 69: 1122-1122. DOI: 10.1158/0008-5472.Sabcs-09-1122 |
0.612 |
|
| 2009 |
Bilal E, Ganesan S, Bhanot G. Abstract C34: Amplifiedlocion chromosomes 8 and 17 predict Tamoxifen resistance in ER+ breast tumors Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-C34 |
0.594 |
|
| 2009 |
Bilal E, Rabadan R, Alexe G, Fuku N, Ueno H, Nishigaki Y, Fujita Y, Ito M, Arai Y, Hirose N, Ruckenstein A, Bhanot G, Tanaka M. 2. mtDNA Haplogroup D4a is a Marker for Extreme Longevity in Japan Mitochondrion. 9: 61. DOI: 10.1016/J.Mito.2008.12.004 |
0.486 |
|
| 2008 |
Bilal E, Rabadan R, Alexe G, Fuku N, Ueno H, Nishigaki Y, Fujita Y, Ito M, Arai Y, Hirose N, Ruckenstein A, Bhanot G, Tanaka M. Mitochondrial DNA haplogroup D4a is a marker for extreme longevity in Japan. Plos One. 3: e2421. PMID 18545700 DOI: 10.1371/Journal.Pone.0002421 |
0.515 |
|
| 2007 |
Alexe G, Fuku N, Bilal E, Ueno H, Nishigaki Y, Fujita Y, Ito M, Arai Y, Hirose N, Bhanot G, Tanaka M. Enrichment of longevity phenotype in mtDNA haplogroups D4b2b, D4a, and D5 in the Japanese population. Human Genetics. 121: 347-56. PMID 17308896 DOI: 10.1007/S00439-007-0330-6 |
0.5 |
|
| Show low-probability matches. |